Olema Pharmaceuticals, Inc. OLMA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Olema Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Olema Pharmaceuticals, Inc.'s cash & equivalents?
- Olema Pharmaceuticals, Inc. (OLMA) reported cash & equivalents of $52.55M in Q1 2026.
- How has Olema Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Olema Pharmaceuticals, Inc.'s cash & equivalents increased by 3.8% year-over-year, from $50.64M to $52.55M.
- What is the long-term trend for Olema Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Olema Pharmaceuticals, Inc.'s cash & equivalents has grown at a -32.3% compound annual growth rate (CAGR), from $338.55M to $48.3M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.